Targeting known variants for cancer related genes

Fixed and custom panels for cost-effective sequencing and easier data analysis

Illumina offers a broad portfolio of cancer panels and cancer-focused products across multiple application areas. These products have been optimized with clinical cancer research in mind.

Achieve sequence-ready libraries from as little as 1 ng of high-quality input or 10 ng formalin-fixed paraffin-embedded (FFPE) sample using efficient, optimized assays and integrated sequencing and bioinformatics. Our comprehensive offering includes both fixed panels and custom options.

Cancer Panels for Targeted Sequencing

AmpliSeq for Illumina and our TruSight cancer panels offer several library preparation, sequencing, and data analysis options for cancer research. Streamlined library prep workflows and flexible kit configurations accommodate multiple study designs. Illumina systems deliver industry-leading sequencing—in fact, more than 90% of the world’s sequencing data are generated using Illumina sequencing by synthesis (SBS) chemistry.*

Select your application area below to find out more about our product offerings for cancer research.

Knowledge is Power: Unlocking the Potential of the Genome

New survey finds Americans unaware of DNA's power to improve lives.

Read Article
Unlocking the Potential of the Genome
Multisite Validation of Solid Tumor Panel

Multi-Site Analytical Validation of TruSight Tumor 15 (TST15) Determining Robustness and Concordance

Read Paper
New Views of Cancer Pathways in Pediatric Leukemia

Researchers are using the TruSight RNA Pan-Cancer Panel to understand the role of fusion genes in pediatric leukemia.

Read Article
Accurate Identification of Cancer Biomarkers

Dr Ravindra Kolhe and his team use TruSight Tumor 170 to study a wide number of variants associated with solid tumors.

Read Article
The Changing Landscape of NGS in Molecular Testing

Key opinion leaders discuss why they see molecular genetics labs moving to multigene NGS cancer panels in the future.

Read Interview
The Changing Landscape of NGS in Molecular Testing
Removing Cancer's Veil: TruSight Tumor 170

A new enrichment-based cancer research assay interrogates both DNA and RNA, detecting small variants, gene amplifications, gene fusions, and splice variants.

View Video
Resources for Onboarding NGS
Resources for Onboarding NGS

View educational resources from recognized oncology experts and regulatory bodies about onboarding NGS.

View Resources
Interested in receiving newsletters, case studies, and information on cancer genomics?
Sign Up
Amplicon Sequencing
Amplicon Sequencing

Ultra-deep sequencing of PCR amplicons enables analysis of specific genomic regions of interest.

Learn More
Cancer Panels Demonstrate Value in Tumor Studies
Cancer Panels Demonstrate Value in Tumor Studies

Clinical researchers share how TruSight Tumor 170 and TruSight Oncology 500 can play an important role in tumor characterization.

Read Interview

*Data calculations on file. Illumina, Inc. 2017.